When will we learn? [1] (multiple letters)

Arthur E. Baue*, Helen Galley, Nigel Webster

*Corresponding author for this work

Research output: Contribution to journalLetter

Abstract

To the Editor:
How or why is it that Paterson et al. (1) can write in Critical Care Medicine on the effects of N-acetylcysteine (NAC), indicating it “may be useful in blunting the inflammatory response to sepsis,” without citing Molnar et al. (2), who described a negative clinical trial? The trial by Molnar et al. (2) was a prospective, randomized, placebo-controlled trial of 86 patients. In fact, Molnar et al. (2) stated “the initiation of NAC treatment 24 hrs after hospital admission may potentially be harmful.” Pinsky (3), in an accompanying editorial to Paterson et al. (1), states, “still, this report places NAC firmly in the area of potential clinical treatment.” He, also, does not cite Molnar et al (2). When will we learn?
Original languageEnglish
Number of pages1
JournalCritical Care Medicine
Volume32
Issue number4
DOIs
Publication statusPublished - 1 Jan 2004

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Fingerprint Dive into the research topics of 'When will we learn? [1] (multiple letters)'. Together they form a unique fingerprint.

  • Cite this